Context Therapeutics (CNTX) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Context Therapeutics (CNTX) has outperformed Psyence Biomedical (PBM) over the past year, losing 85.3% versus a loss of 94.9%. Psyence Biomedical is the larger company by market cap ($15.8 million vs $14.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | PBM |
|---|---|---|
| Share price | $0.16 | $2.97 |
| Market cap | $14.70M | $15.80M |
| 1-day change | -5.10% | +3.85% |
| YTD return | -89.12% | -89.90% |
| 1-year return | -85.32% | -94.90% |
| 5-year return | -96.86% | — |
| EPS (TTM) | $-0.46 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-36.12M | $1.01M |
| 52-week high | $3.62 | $73.44 |
| 52-week low | $0.153 | $1.92 |
| Distance from 52-week high | -95.58% | -95.96% |
| Analyst consensus | none | — |
| Avg. price target upside | +2418.75% | — |
| Average volume | 1.42M | 61.93K |
| Shares outstanding | 91.88M | 5.32M |
| Employees | 15 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
CNTX vs PBM FAQ
Which is bigger, Context Therapeutics or Psyence Biomedical?
Psyence Biomedical (PBM) is larger, with a market capitalization of $15.80M compared with $14.70M for Context Therapeutics (CNTX).
Which stock has performed better over the past year, CNTX or PBM?
CNTX returned -85.32% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.